Effects of the Alkylating Agent Cyclophosphamide in Potentiating Anti-Tumor Immunity
International Journal of Molecular Sciences · 04.07.2025 · 26 (13) · 6440
DOI: 10.3390/ijms26136440 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.07.2025. Verfasst von Benjamin D Gephart und 2 weiteren Autor:innen. Beteiligte Einrichtung: Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA. Hauptthemen laut MEDLINE: Cyclophosphamide, Neoplasms, Antineoplastic Agents, Alkylating. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, Pediatric Cancer Research Group,.
Abstract (Originalsprache)
Cyclophosphamide (CPX) is an alkylating agent commonly used for various hematological and solid malignancies. In addition to its use as a cytotoxic agent to directly kill tumor cells, numerous immunomodulatory properties of CPX in the tumor microenvironment (TME) of several cancer types have also been documented. These properties include the selective depletion of immune-suppressive regulatory T cells (Tregs), triggering of immunogenic cell death (ICD) and enhanced antigen presentation, and release of type I interferons (IFNs). Moreover, preclinical models as well as human clinical trials have investigated the efficacy of the low-dose “metronomic” scheduling of CPX in combination with immunotherapies such as immune checkpoint inhibitors, dendritic cell tumor vaccines, and tumor antigen peptide vaccines. The metronomic dosing schedule involves administering a continuous (or frequent, such as daily) low dose of chemotherapy rather than using the canonical approach of administering the maximum tolerated dose. Despite the approval of immune checkpoint inhibitors for clinical usage against an increasing number of cancers, many malignancies simply do not respond to checkpoint inhibition, in part due to the heterogeneous intratumoral network of immune-suppressive cell populations. The immunomodulatory effects of cyclophosphamide have strong translational applicability and could serve to enhance and bolster anti-tumor immunity, potentially synergizing with immune checkpoint inhibitors and other existing immunotherapy agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Children's Nebraska, Omaha, NE 68198, USA.
- Department of Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Department of Pathology, Microbiology & Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
ORCID-Profile: Don W Coulter
Förderung
- NIH HHS
- NCI NIH HHS
- Pediatric Cancer Research Group,
- Pediatric Cancer Research Group, part of the Child Health Research Institute
- National Cancer Institute (NCI)-supported Cancer Biology Training Program
- Fred & Pamela Buffett Cancer Center NCI Cancer Center
Zitieren
APA
Gephart, B. D., Coulter, D. W., & Solheim, J. C. (2025). Effects of the Alkylating Agent Cyclophosphamide in Potentiating Anti-Tumor Immunity. International Journal of Molecular Sciences, 26(13), 6440. https://doi.org/10.3390/ijms26136440
Vancouver
Gephart BD, Coulter DW, Solheim JC. Effects of the Alkylating Agent Cyclophosphamide in Potentiating Anti-Tumor Immunity. International Journal of Molecular Sciences. 2025;26(13):6440. doi:10.3390/ijms26136440
BibTeX
@article{Gephart2025,
author = {Gephart, Benjamin D and Coulter, Don W and Solheim, Joyce C},
title = {Effects of the Alkylating Agent Cyclophosphamide in Potentiating Anti-Tumor Immunity},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {13},
pages = {6440},
doi = {10.3390/ijms26136440}
}
EUVIMED